Operator of a biotechnology company intended to develop differentiated disease therapies based on the targeted protein stabilization platform. The company's protein stabilization platform addresses protein instability and degradation, and haploinsufficiency diseases by slowing the turnover rates of the remaining gene and protein, enabling healthcare professionals to have novel therapeutics for cancer and genetic disorders.